Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of difelikefalin (MR13A9) dose response for pruritus
jRCT2080224518Phase 2Completed
- Start
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of difelikefalin in pruritus. Primary endpoint: NRS score for pruritus. Started Jan 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
pruritus
Beyond the preview
Go deeper on jRCT2080224518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224518.